Zacks Research Has Bearish Estimate for Hologic Q3 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for Hologic in a research note issued to investors on Wednesday, May 21st. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $1.05 per share for the quarter, down from their previous forecast of $1.08. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q4 2025 earnings at $1.08 EPS, FY2025 earnings at $4.20 EPS, Q1 2026 earnings at $1.05 EPS, Q2 2026 earnings at $1.07 EPS, Q3 2026 earnings at $1.11 EPS, Q4 2026 earnings at $1.16 EPS, FY2026 earnings at $4.39 EPS, Q1 2027 earnings at $1.13 EPS, Q2 2027 earnings at $1.18 EPS and FY2027 earnings at $4.80 EPS.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period in the prior year, the firm posted $1.03 EPS. The company’s quarterly revenue was down 1.2% on a year-over-year basis.

Several other brokerages have also commented on HOLX. Morgan Stanley cut their target price on Hologic from $77.00 to $65.00 and set an “equal weight” rating on the stock in a research report on Monday, May 5th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Finally, Raymond James restated an “outperform” rating and issued a $71.00 price target (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $77.42.

Hologic Stock Performance

Shares of Hologic stock opened at $54.28 on Friday. The business has a 50-day moving average price of $58.17 and a two-hundred day moving average price of $66.61. Hologic has a 1-year low of $51.90 and a 1-year high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $12.10 billion, a P/E ratio of 17.12, a PEG ratio of 2.14 and a beta of 0.54.

Hedge Funds Weigh In On Hologic

Several large investors have recently bought and sold shares of HOLX. Venturi Wealth Management LLC raised its holdings in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. Zions Bancorporation National Association UT purchased a new position in Hologic during the first quarter worth about $34,000. EverSource Wealth Advisors LLC grew its position in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 260 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares during the last quarter. Finally, Smithfield Trust Co lifted its position in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 400 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Martin D. Madaus bought 5,445 shares of the business’s stock in a transaction that occurred on Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.